Updated time: 2023-01-18 13:51:47
The IL-1beta-specific antibody, IgG26AW, was developed by screening a human phage-displayed library and optimized by a structure-based design. We validated IgG26AW-neutralizing ability in vivo. We also treated IgG 26AW with xenograft mice bearing lung or breast cancer, this unique antibody also made the tumor shrank and inhibited tumor metastasis.
IgG26AW neutralizes the biological activity of IL-1beta by blocking the binding of IL-1beta to the cell surface receptor IL-1R and its association with IL-1RAcP. IgG26AW has a better neutralization ability of IL-1beta than Canakinumab, clinical used for now. This means that we can treat patients with a smaller dosage of drugs, which can reduce costs, side effects, resistant response or antidrug antibodies.

Fig1. 26-Fab blocked the formation of IL-1b/IL-RI/IL-1RAcP ternary complex
11A-1090117
2020-12-03
TW I788880、US porvisional
- Rheumatoid arthritis
- Osteoarthritis
- Cardiovascular disease
- Type II Diabetes
- cancer related complimentary treatment
- immune suppressor drugs
Andrew H. –J. Wang、Wen-Chih Kuo、Cheng-Chung Lee、An-Suei Yang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Fig2. IgG26AW blocked IL-1b induced IL-6 secretion (C)

Antibodies of Interleukin-1beta and Uses Thereof